5 Healthcare Stocks to Watch Amid Senate’s Healthcare Bill

2. Johnson & Johnson (NYSE:JNJ)

Number of Hedge Fund Holders: 83

Johnson & Johnson (NYSE:JNJ) is a pharmaceutical company operating worldwide. It offers baby care products, oral care products, and skin health/beauty products, among others.

A ‘Neutral’ rating was reiterated on Johnson & Johnson (NYSE:JNJ) shares this month by UBS analyst Kevin Caliendo. Caliendo also lowered the price target on the stock to $180, from the previous $185 target.

Johnson & Johnson’s (NYSE:JNJ) antipsychotic Invega franchise and Darzalex Faspro may face negotiated prices by 2026 and 2033 respectively, several years before their time. The former is forecasted to bring in $3.3 billion in 2026 in U.S. sales alone. Government interference with the product’s price may cause problems for Johnson & Johnson (NYSE:JNJ) in the future.

There were 83 hedge funds long Johnson & Johnson (NYSE:JNJ) in the first quarter, with a total stake value of $7.4 billion. 83 hedge funds were also long the stock a quarter earlier, holding a combined $7.3 billion in shares.